NeuroBo Pharmaceuticals News

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Nov 4 21:34

NeuroBo Pharmaceuticals | 8-K: Posted an Updated Corporate Presentation to Its Website

Oct 7 19:03

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 30 20:08

NeuroBo Pharmaceuticals | 8-K: Company Held a Virtual Special Meeting of Stockholders

Sep 20 04:15

NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements

Aug 22 04:06

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14 20:05

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 13 20:32

NeuroBo Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Aug 7 20:01

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces Joint Research Agreement

Aug 6 20:33

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Announces Exclusive License Agreement with Mthera Pharma for Nb-01

Jul 30 20:35

NeuroBo Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Jul 18 20:26

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Jul 16 20:32

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 26 21:18

NeuroBo Pharmaceuticals | 8-K: Entered into a Securities Purchase Agreement

Jun 25 20:05

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, And Lipid-Lowering Effects Compared to Survodutide, In Pre-Clinical Models

Jun 24 18:06

NeuroBo Pharmaceuticals | 8-K: Poll Results of NeuroBo Pharmaceuticals Meeting

Jun 8 04:11

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals’ DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 22 20:34

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9 20:07

NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements

Apr 30 20:45

NeuroBo Pharmaceuticals | 8-K: NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 30 20:35